Stockscreener 앱 받기
0.012
2.44%
-0.0003
시간 외 거래:
.01
-0.002
-16.67%
Vincerx Pharma Inc 주식(VINC)의 최신 뉴스
Vincerx Pharma, Inc. (VINC) Stock forecasts - Yahoo
Analyzing Neoleukin Therapeutics (NASDAQ:NLTX) & Vincerx Pharma (NASDAQ:VINC) - Defense World
Vincerx Pharma, Inc. (VINC) stock price, news, quote and history - Yahoo
Vincerx Pharma, Inc.Common Stock (NQ: VINC - FinancialContent
Vincerx Pharma ends sales agreement, approves reverse stock split - MSN
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VINC, NEUE, ZUO on Behalf of Shareholders - ACCESS Newswire
Vincerx Pharma (NASDAQ:VINC) vs. NovaBay Pharmaceuticals (NYSE:NBY) Financial Survey - Defense World
Vincerx Pharma, Inc. Announces Additional Adjournment of - GlobeNewswire
Vincerx Warns Stockholders: Delayed Dissolution Vote Threatens $0.07 Per Share DistributionAction Required - Stock Titan
Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders - The Manila Times
Vincerx announces potential distribution of $0.04-$0.08 per share By Investing.com - Investing.com South Africa
Vincerx announces potential distribution of $0.04-$0.08 per share - Investing.com
Vincerx Pharma, Inc. Urges Stockholders to Vote FOR - GlobeNewswire
Vincerx Pharma Stockholders Face Critical July 16 Vote: $0.08 Per Share at Stake in Dissolution Plan - Stock Titan
Vincerx Pharma enters at-the-market equity offering deal - MSN
Vincerx Pharma, Inc. Announces Adjournment of Special MeetingWill Reconvene Meeting on July 16, 2025 to Secure Votes Needed to Approve Dissolution Proposal - GlobeNewswire
Vincerx Pharma Stockholders Risk Losing All Distribution Value if Dissolution Vote Fails by July 16 - Stock Titan
At a crossroads, biotechs are passing on reverse mergers in 2025 - Endpoints News
TC BioPharm’s $100M Shelf Offering: A Beacon of Resilience in a Collapsing Biotech Landscape - AInvest
VINC Stock Price and Chart — OTC:VINC - TradingView
VINC stock touches 52-week low at $0.17 amid sharp annual decline - Investing.com UK
Nasdaq to delist Vincerx Pharma by April 23 - Investing.com India
vincerx pharma cancels merger, initiates wind-down activities By Investing.com - Investing.com UK
Vincerx prepares to wind down as final merger attempt collapses - Fierce Biotech
Financially struggling drugmaker's potential rescue falls apart. It now will wind downSan Francisco Business Times - The Business Journals
Vincerx Pharma Inc Initiates Wind Down and Asset Monetization - TipRanks
VINC Stock Plummets to 52-Week Low of $0.48 Amid Steep Decline - Investing.com
Vincerx Pharma (VINC) Projected to Post Quarterly Earnings on Friday - Defense World
Vincerx Pharma Inc. (VINC) reports earnings - qz.com
Vincerx Pharma Inc expected to post a loss of $3.40 a shareEarnings Preview - TradingView
Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI - GlobeNewswire
Finance Watch: Sutro Halves Workforce, Cuts Lead ADC And CEO Moves On - insights.citeline.com
Vincerx Pharma Plunges After Scrapping Reverse Merger With Oqory And Vivaso - Nasdaq
Vincerx Pharma Announces Termination of Reverse Merger Term Sheet and Evaluation of Strategic Alternatives - GlobeNewswire
VINC stock touches 52-week low at $1.3 amid market challenges - Investing.com
Vincerx Pharma, Inc. and Oqory, Inc. Highlight Promising Data for Oqory’s TROP2 Antibody Drug Conjugate, OQY-3258 - Yahoo Finance
Vincerx Pharma, Inc. Announces 1-for-20 Reverse Stock Split Effective January 27, 2025 - Nasdaq
Palo Alto's Vincerx Pharma plans reverse stock split amid merger plans - The Business Journals
Vincerx Pharma, Inc. Announces Reverse Stock Split - GlobeNewswire
Vincerx Pharma ends sales agreement, approves reverse stock split By Investing.com - Investing.com UK
Investor law firms question biotech merger's 'fairness' - The Business Journals
Kahn Swick & Foti, LLC Investigates Merger of Vincerx Pharma, Inc.VINC | FinancialContent - FinancialContent
Fierce Biotech Layoff Tracker 2024: Vincerx reduces workforce; Novartis lays off 330 staffers - Fierce Biotech
PRN_FinancialWrapper - FinancialContent
Vincerx Pharma Stock Rises On Proposed Merger With Oqory: Retail Remains Bullish - Stocktwits
Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc. - Yahoo Finance
Vincerx Pharma Stock Gets Retail Followers Buzzing With Big Layoff Plans To Sustain Cancer Drug Trials - Stocktwits
Vincerx Pharma Reports Promising Cancer Drug Results, Explores Strategic Options Amid Cost Cuts - Stock Titan
Vincerx Pharma Inc (VINC) Quarterly 10-Q Report - qz.com
What Makes Vincerx Pharma (VINC) a New Buy Stock - Yahoo Finance
VINC Stock Touches 52-Week Low at $0.51 Amid Market Challenges - Investing.com
Vincerx Reports Positive Initial Clinical Data from Ongoing VIP943 Phase 1 Dose-Escalation Study and Provides Pipeline and Corporate Updates - Yahoo Finance
Vincerx Pharma Announces Stock Option Repricing and Shareholder Approval - TipRanks
10 Best Biotech Penny Stocks to Buy Now - Insider Monkey
Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrants - Investing News Network
Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants - Investing News Network
Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update - Investing News Network
Vincerx Pharma announces proposed underwritten public offering of common stock and warrant - Seeking Alpha
Vincerx Blames Stock Plunge On Overheated ADC Expectations - insights.citeline.com
Why Is Vincerx Pharma (VINC) Stock Down 64% Today? - InvestorPlace
Vincerx reports positive early trial results for cancer drugs - Investing.com
Vincerx Pharma Inc reports results for the quarter ended in DecemberEarnings Summary - TradingView
Pre-market Movers: NKGN, CELZ, AFMD, EVA, VINC.... - RTTNews
Vincerx to Present Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024 - Stock Titan
Why Is Cancer Focused Penny Stock Vincerx Pharma Trading Higher Today? By Benzinga - Investing.com UK
Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma - Yahoo Finance
Vincerx Pharma Presents Preclinical VIP943 and VIP924 Posters at ASH 2023 - Yahoo Finance
Vincerx Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update - GlobeNewswire
Vincerx Pharma Doses First Patient in the Phase 1 Clinical Trial Evaluating VIP943 - Stock Titan
Vincerx Pharma Announces FDA Clearance of IND for VIP943 - GlobeNewswire
Andrew I Mcdonald Net Worth (2025) - GuruFocus
1.44%
0.91%
자본화:
|
볼륨(24시간):